{"nctId":"NCT05780437","briefTitle":"AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","startDateStruct":{"date":"2021-02-10","type":"ACTUAL"},"conditions":["COVID-19"],"count":1455,"armGroups":[{"label":"AZD7442 plus SOC","type":"EXPERIMENTAL","interventionNames":["Biological: AZD7442","Biological: Remdesivir"]},{"label":"Placebo plus SOC","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo","Biological: Remdesivir"]}],"interventions":[{"name":"AZD7442","otherNames":["AZD8895 + AZD1061"]},{"name":"Placebo","otherNames":[]},{"name":"Remdesivir","otherNames":["Veklury"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nâ€¢ Refer to the master protocol (NCT04501978)\n\nExclusion Criteria:\n\n* Refer to the master protocol (NCT04501978)\n* Additional Exclusion Criteria:\n\n  * Pregnant women\n  * Nursing mothers\n  * Women of child-bearing potential who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with men or practice appropriate contraception through the entire 18 months of the study\n  * Men who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through the entire 18 months of the study.\n* In addition, prior to the initial futility assessment which is performed when approximately 150 participants have been enrolled on AZD7442 and 150 on placebo, patients on high-flow oxygen or non-invasive ventilation (category 5 of the pulmonary ordinal outcome) will be excluded. These patients may be eligible for the trial if the initial futility assessment is passed by this agent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Sustained Recovery","description":"The primary endpoint is the proportion of subjects with sustained recovery, which is defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90. Home is defined as the level of residence or facility where the participant was residing prior to hospital admission leading to enrollment in this protocol. Readmission from \"home\" may occur, and if this occurs within 14 days of the first discharge to \"home,\" then the primary endpoint will not be reached until such time as the participant has been at home for 14 consecutive days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"617","spread":null},{"groupId":"OG001","value":"594","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With an Ordinal Outcome on Day 5","description":"Ordinal outcome with 7 mutually exclusive categories","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"99","spread":null}]},{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"106","spread":null}]},{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"126","spread":null}]},{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"199","spread":null}]},{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Safety Outcome Through Day 5","description":"Safety outcomes are defined as Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 5. Seriousness was based on the definition of the term at 21CFR312.32\n\nAEs were graded for severity by the treating investigator, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (also known at the DAIDS AE Grading Table), U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. \\[July 2017\\]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf). The following generic grading descriptions from the DAIDS AE Grading Table are provided for context: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"202","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Safety Outcome Through Day 28","description":"Safety outcomes are defined as Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 28. Seriousness was based on the definition of the term at 21CFR312.32\n\nAEs were graded for severity by the treating investigator, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (also known at the DAIDS AE Grading Table), U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. \\[July 2017\\]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf). The following generic grading descriptions from the DAIDS AE Grading Table are provided for context: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"250","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Safety Outcome Through Day 90","description":"Safety outcomes are defined as Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 90. Seriousness was based on the definition of the term at 21CFR312.32\n\nAEs were graded for severity according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (also known at the DAIDS AE Grading Table).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"214","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died From All Causes","description":"All-cause Mortality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":710},"commonTop":["Dyspnea","Fatigue","Hypoxia","Hypotension","Cough"]}}}